瑞士巴塞尔大区经济及创新促进局欢迎您

在瑞士最具活力的经济地区培育创新,加速业务发展  >>>>

最瑞士

瑞士是亲商、可靠和高效的代表。巴塞尔地区经济强盛,秉承明确的亲商核心价值,是瑞士这些美德的光辉榜样。  >>>>

生命科学和医疗行业第一

整个生命科学价值链汇聚于一处,且触手可及?这是600家及越来越多的公司对巴塞尔地区情有独钟,将其作为研发、生产和总部的原因。  >>>>

创新行业第一

多项研究结果表明,瑞士是全球最具创新精神的国家。巴塞尔地区丰富的知识、高素质国际人才和强有力的产业支柱使瑞士成为领先的创新枢纽。  >>>>

往来欧洲交通便利度第一

无论是集装箱运输还是空运,巴塞尔地区都拥有交通便利的优势。它与德国和法国接壤,位于欧洲中部的中心地带,是国际贸易青睐的物流枢纽和城市平台。  >>>>

文化和休闲第一

世界级艺术珍宝、文化和体育活动,融入健康自然娱乐景观中的国际化都市氛围,所有这些因素结合在一起,使巴塞尔地区成为全球最适宜居住和工作的地区之一。  >>>>

瑞士巴塞尔大区经济及创新促进局是瑞士西北地区巴塞尔乡村州、巴塞尔城市州和汝拉州为促进创新和经济发展而联合成立的机构。本机构旨在帮助国外企业家和公司在巴塞尔地区成功实践创新,创立公司。

我们拥有15,000名决策者、创新者、专家、影响者和增值者组成的广泛关系网络,让客户能直接获取相关专业知识和技术。

瑞士巴塞尔大区经济及创新促进局主要在以下四个领域内为客户提供定制化服务:

  • 投资巴塞尔地区:提供个性化支持,帮助客户在巴塞尔地区择址。本机构将在整个择址和入驻过程中为公司提供中肯的建议。
  • 为创新着牵线搭桥:帮助生命科学、医疗技术、信息通信技术(ICT)、微技术、纳米及材料和生产技术领域的公司和研究人员在技术、研发和创新事务方面建立联系。
  • 支持创业:为计划在巴塞尔创业的企业家提供全面支持,在其商业计划的运营执行过程中进行协助。此外,以上技术领域中处于扩张模式的初创公司和中小型公司可从策略性交流服务中受益,与行业专家和投资人建立联系。
  • 进驻中国:为瑞士西北部地区寻求扩张到中国的公司提供适当的合作伙伴网络,协助其顺利进驻中国市场,执行扩张项目。

瑞士巴塞尔大区经济及创新促进局还管理着一个综合性信息平台,展示巴塞尔商业地区的优势和专长领域,进一步促进该区域创新公司的融入:

  • “创新报告”:涵盖巴塞尔地区最新创意活动和报告,每月发布一次新闻简报,内容包含采访、背景故事和公司入驻本地的消息。
  • “创新活动”:瑞士巴塞尔大区经济及创新促进局每年组织并合办逾50次专门针对知识转移和创业文化的活动。在“创新活动”中,创新者和企业家分享他们最新的创新理念和经验。

在竞争力和创新能力方面,瑞士已多年位居世界顶级营商目的地前列。多个因素保证了瑞士的领先地位。除了优良的教育和先进的基础设施外,让瑞士等同于亲商、可靠和高效的另一个重要原因就是高效的瑞士政府机构。几十年来,瑞士强有力的法律系统、可靠的规划和稳定的金融体系使得在瑞士经营的公司及其在这里的投资项目都受益匪浅。这种环境也是企业向新市场持续扩张的一个最重要的前提条件。瑞士跨国公司密度全球最高绝非偶然。

巴塞尔地区对瑞士的成功做出了重大贡献。众多国际领先跨国公司不仅发迹于此,这些公司的成功也为该地区的经济增长注入强劲动力。例如,巴塞尔地区的GDP远高于瑞士全国平均水平。大巴塞尔地区人均国内生产总值为瑞士最高。与此同时,巴塞尔在生命科学和其他高科技领域的领先优势推动了瑞士创新能力的发展。例如,瑞士约有占总值五分之一的出口货物在巴塞尔地区制造,考虑到巴塞尔地区人口仅占瑞士人口不到10%,这是十分了不起的成就。

在全球商业、产业和知识竞争力方面,瑞士,特别是巴塞尔地区享有的美誉主要体现在以下四个突出优势上:

  • 明智的税收政策:瑞士采用的联邦制度鼓励州与州之间的财政竞争,使税收保持在合理的范围内。除了联邦层面的统一税率外,各州可自主确定税率,并为公司提供最佳的营商环境。由此,巴塞尔地区的主要受益人是活跃在创新行业、具有高附加值的公司,以及大力投资研发和生产的公司。
  • 自由的劳力市场:由于巴塞尔地区拥有众多活跃于国际的高科技公司,地方政府对于他们对海外高素质专家和高级管理人员的需求采取支持态度。这一欧洲最自由的劳动市场之一使得企业从中受益,同时也给予员工巨大利益。巴塞尔地区的劳动法规和劳力市场使得公司可以在营商环境发生变化并需采取相应措施时能够做出快速反应。
  • 可持续的基础设施:在瑞士,火车晚点5分钟就会令人不快,但这种情况极少发生。这一点常令外国访客露出满意的笑容。众所周知,瑞士的公共基础设施堪称世界上最先进、最可靠的,而巴塞尔地区的优势正在于此。交通四通八达,通过公路、铁路和飞机航线可往返欧洲各地,通过莱茵河的水路可通向全球。
  • 双轨制教育体系:瑞士仅三分之一的年轻人高中毕业后选择继续在瑞士顶尖大学深造。对于很多国家来说,这也许是教育体系的重大失职。但是实际上,这是瑞士在专业技术上成功的一部分原因。瑞士双轨制教育体系旨在确保大多数年轻人完成瑞士联邦认证的学徒期,以尽早参加工作。年轻人可以(也通常会)在瑞士技术学院或应用科学类大学获取专业学位,大多是在职学位。这为瑞士劳力市场稳定提供了经过多年在职培训的入门级雇员,这些人员可以在最具发展潜力的行业进行灵活就业,而雇主和行业实际上也需要这样的人才。此外巴塞尔地区的独特优势在于其拥有众多完善的国际学校,这些学校能够满足外籍人士及其子女的需求,帮助他们轻松融入当地。

作为唯一一个基于直接民主制的政治体系,瑞士在几百年里建立起独特的具有凝聚力的政治和社会文化。其特点是联邦制、自治和一致性,是稳定的政治和社会环境的基石,也是瑞士价值观的体现。巴塞尔地区政府及其民众的开放思想和进取态度,使其成为营商目的地的典范,为企业提供了优良的发展环境,推动企业不断发展壮大。

巴塞尔地区是生命科学领域全球最受欢迎的目的地之一,在欧洲更是无出其右。作为全球市场前三强的罗氏和诺华都是从巴塞尔地区起家,继而将业务拓展至全球。

与之类似的其他跨国公司也在巴塞尔建立了其中心业务分部,其中包括礼来、雅培和拜耳。Actelion、Basilea和Evolva等众多新入驻的公司以及Bachem和Polyphor这样高度专业化的公司使得巴塞尔形成完整的生命科学生态系统。并不令人意外的是,巴塞尔地区还演变成具有发展前景的初创公司钟爱的热点地区。

巴塞尔地区有共计700家生命科学公司,它们对该地区业已颇具活力的营商环境做出重大贡献。这些企业的持续成功主要基于以下三个因素:

  • 生命科学行业是巴塞尔地区经济增长的引擎。这个行业在此生根发芽,且枝繁叶茂:巴塞尔地区生命科学行业的雇员共计3.3万名,每小时生产的产品和服务价值高达3.21亿美元。这使巴塞尔地区成为全球生产力最高的生命科学目的地。巴塞尔地区的生产总值也位居全球之冠:巴塞尔地区的产量全球最高,年产值达190亿美元。与此同时,巴塞尔地区每年获得60亿美元研发投资,是全球这方面数额最高的地区。本地生命科学使经济增长高于瑞士全国平均水平,这使得该行业在巴塞尔地区的声誉无可挑剔。
  • 巴塞尔地区拥有各类人才和专家,而且人数众多:从研发、创办公司到制造、营销和分销,巴塞尔地区拥有一条完整的生命科学价值链,因此您能找到企业在各个发展阶段和各个职能所需的人才和专家。他们人数众多,且经验丰富。加上顶尖的研究机构,如巴塞尔大学生物研究中心(Biozentrum)、苏黎世联邦理工学院(ETHZ)生物系统科学与工程学院和弗雷德里希•米歇尔研究所(FMI),您大致可以了解到巴塞尔地区独特的生命科学资源组合的范围有多广。该地区有触手可及的资源、技术和人才,其深度和密度在全球范围都无可匹敌。这为未来创新提供了独一无二的肥沃土壤。
  • 巴塞尔地区作为生命科学行业的创新标杆已有逾250年的历史:因此巴塞尔地区可谓是涉足生命科学领域历史最悠久的地区。从十九世纪中叶的工业丝带染坊到生物技术革命,巴塞尔的生命科学生态系统不断演进,并在行业的巨大发展中实现了自身突破。这一光辉故事将被续写。与其他曾经实现发展的生命科学中心不同的是,巴塞尔地区在过去几年一直保持稳定和持续的增长。该地区未来几年计划在公共和私人基础设施项目上将投入60亿瑞士法郎,因此下一个高增长期指日可待。

传统优势、强有力的产业支柱、深厚的研发和商业化专长,使得巴塞尔地区成为全球最为完善和成熟的生命科学目的地。您很难再找到另一个像巴塞尔这样适合在生命科学领域高效、可持续和成功地开发科研及商业项目的地区。

高科技是巴塞尔地区经济的推动力,并且是本地经济增长高于平均水平的保障。而且这种局势将持续下去。强有力的产业支柱、吸引全球人才和专家的国际化营商环境,加上瑞士世界一流的教育体系,使巴塞尔地区成为创新的理想环境。在这里,企业,尤其是医疗技术、信息与通信技术、精密机械以及化工业公司都将从该地区的以下特点中受益:                       

  • 巴塞尔地区拥有深厚的高科技产业基础:巴塞尔城市州92%的产业附加值来自高科技公司。类似地,在巴塞尔乡村州和汝拉州,该比例远高于70%,因此高于瑞士60%的平均水平。而瑞士60%的平均水平已使其跻身于世界最具创新精神的国家之列。
  • 巴塞尔地区是研发领域领头羊:瑞士私营部门的研发投资比例高达69%,在全球范围内都属于较高比重。其中40%来自巴塞尔地区,而本地人口仅占瑞士人口的10%。瑞士国内专利最多的十家公司中有五家的总部位于巴塞尔地区,它们是罗氏、诺华、科莱恩、先正达和Endress+Hauser。这也是为什么巴塞尔地区成为瑞士国内聘请研发人员最多的地区。
  • 巴塞尔地区与全球紧密联系,吸引着世界各地的人才:巴塞尔70万居民中约有五分之一来自海外;当前外籍人士达到3.6万人。巴塞尔地区与德法两国接壤,每天有7万名跨境上班族从邻国流入。很难再找到一个地区,像巴塞尔地区这样在如此小的区域内拥有如此具有活力的国际商务氛围,并吸引着全球各地的专业人才汇聚一处。
  • 世界一流的科学和学术教育:除了是强大的产业研发中心外,巴塞尔地区在欧洲学术界举足轻重。巴塞尔大学拥有2,000名教授和1.2万名学生,是欧洲历史最悠久的大学之一,位居全球100所大学之列。从巴塞尔地区乘火车,2小时内即可到达苏黎世联邦理工学院(ETHZ,在巴塞尔设有生命科学学院)和洛桑理工学院(EPFL)。这两所大学都是全球绝对一流的大学。巴塞尔地区(包括其交界国)数百公里范围内共有167家研究机构。此外,瑞士的双轨制教育体系和瑞士西北应用科学大学稳定提供训练有素的高技能专业人才。

研究和调查结果显示,瑞士多年来一直都是全球领先的创新地区之一。强有力的产业支柱、吸引全球人才的全面国际化营商环境,再加上瑞士学术和双轨教育体系,使巴塞尔成为瑞士的创新枢纽。巴塞尔地区的资源密度可谓独一无二:在巴塞尔地区,最高水平的科学表现、行业专长和技术,以及高素质的劳动力都触手可及。


早在罗马帝国时期,巴塞尔莱茵港口就是通向北海航道的最南端港口。1226年,博登湖和北海之间的莱茵河段上建成第一座桥梁(也是此后多年唯一一座),使得巴塞尔演变为重要的贸易枢纽。巴塞尔地区与德国和法国接壤,位于欧洲中部的中心地带,保持了其作为瑞士最重要交通和物流枢纽的领先地位,为本地产业和商业带来诸多利益。
此外,巴塞尔地区特别适合计划在欧洲建立全球总部,以及积极追求全球贸易新机遇的公司。巴塞尔地区具有以下独特优势:

  • 巴塞尔地区是欧洲重要的交通枢纽:从市中心乘出租车或公交仅需15分钟即可到达巴塞尔机场。从该机场可到达欧洲、北美和中东的90多个目的地。集装箱从巴塞尔城的三个莱茵河港口发出,三天内可到达鹿特丹港,而后从那里运往全球各地。火车站每个小时就有一列开往瑞士所有主要城市的火车,如苏黎世(包括苏黎世国际机场)、伯尔尼、洛桑和日内瓦,以及莱茵河畔的各个经济中心(即弗莱堡、卡尔斯鲁厄和斯特拉斯堡)。乘坐高铁几个小时就可轻松便捷地到达欧洲各大都市和首都,如法兰克福、巴黎和米兰。
  • 巴塞尔地区是瑞士领先的物流枢纽:巴塞尔的三个莱茵河港口吞吐量占瑞士外贸总量的12%,其中食品和农产品吞吐量高达84.2万吨。整个巴塞尔地区的外贸额占瑞士总量的三分之一。巴塞尔机场是瑞士领先的货运机场。这使得巴塞尔作为物流枢纽的地位名副其实。巴塞尔物流行业拥有2.3万名从业人员。990家物流公司落户巴塞尔地区,包括市场领导者DHL、Panalpina、Goldrand 和嘉里物流。这些公司可提供成熟的解决方案应对复杂挑战,例如在供应链管理方面,而这正是生命科学和化工业企业常常需要的。
  • 巴塞尔地处欧洲中心位置,是国际贸易公司的理想之选:特种烟草制造商大卫杜夫、零售商Dufry、餐饮公司 Transgourmet 和国际清算银行等各类公司和机构凸显出在巴塞尔交易和提供的货品的多样性。因此瑞士第二大连锁超市Coop和第一大百货公司Manor都选择将总部设在巴塞尔地区。该地区同样是一系列国际贸易展会的重要举办地。每年举办的巴塞尔国际钟表珠宝展(BaselWorld)实现了国际名表和珠宝业的很大一部分销售额。而巴塞尔艺术博览会(Art Basel)则是全球最重要的艺术盛会。越来越多的国际消费品牌已发现巴塞尔作为贸易枢纽的优势,并将欧洲总部设在巴塞尔地区。其中就有美国著名时尚品牌Fossil、自行车制造商Cannondale和时装设计品牌Tally Weijl。

越来越多的跨国公司发现将巴塞尔作为其全球或欧洲总部的吸引力,特别是考虑到巴塞尔出色的连通性和运输系统以及本地在物流和国际贸易上的优势。老字号瑞士公司和初创公司都在利用这里处于欧洲中心所带来的优势。最后,巴塞尔地区毗邻德国和法国,与世界各地交流频繁,本地人口具有世界性,使得整个商业区域生机勃勃,持续增长。

早餐在德国,中餐在法国,晚餐在瑞士:巴塞尔地区地处三国交界处,具备都市化的国际商业氛围,与瑞士其他都市地区相比,人们可以以相对较低的成本享受无与伦比的生活品质。获奖建筑、历史悠久的市中心和从嬉皮士到经典风格的丰富精致的文化生活,都是巴塞尔地区良好城市生活方式的几大支柱。同时,成熟的公共交通系统可快速直达郊区和乡村居住区,以及那里的自然公园和休闲场所。

问一问新来者和新移民:巴塞尔不仅拥有瑞士最大的外籍人士社区,各种国际学校为他们的子女提供教育,而且是定居时间超过5年外籍人士比例最高的地区。原因不止一个:

  • 每个人都能享有巴塞尔的城市生活方式和丰富的文化生活:巴塞尔的根基在罗马和凯尔特人时期就已打下。中世纪末尾至现代初期,该地区首次达到全盛。当然,巴塞尔并未止步于此。现今,巴塞尔繁荣的创意行业、各色当地美味餐馆,以及丰富的文化活动带来了生机勃勃的都市生活方式。在狂欢节时漫步风景如画、历史悠久的市中心,在新巴洛克风格的交响乐厅前停留,或在夏季到明斯特广场观赏户外电影——巴塞尔总是精彩不断。
  • 到了巴塞尔,艺术爱好者就来对了地方:巴塞尔美术馆创立于1671年,被视作历史最悠久的公共社区艺术博物馆。根据伦敦泰晤士报的排名,该馆位列世界5大美术馆之一。另一吸引人的景点是拜尔勒基金会博物馆。该馆由意大利著名建筑师Renzo Piano设计。巴塞尔的另一个艺术重头戏是全球最大的艺术展——巴塞尔艺术博览会(Art Basel)。每年,艺术家、收藏家、画廊和拍卖行以及名流贵宾早早地就在日历里标出博览会举办的日期。他们中有些人会赶来欣赏巴塞尔剧院享誉全球的获奖演出(有歌剧、戏剧和芭蕾舞)。
  • 巴塞尔地区总是充满了运动气息,而且不仅是在体育馆或沙发前的电机上:本地最受欢迎的巴塞尔足球俱乐部(FC Basel)在圣雅各布公园主场迎战欧洲足球顶尖赛事的对手。ATP巡回赛的一流选手参加瑞士室内网球锦标赛,其中包括本地超级球星罗杰·费德勒。在竞技场之外,巴塞尔民众也很热衷于运动。巴塞尔地区自行车使用率为全瑞士最高,包括骑车的上班族和在周边乡间无数自行车道上行进的骑行爱好者。跑步爱好者可在莱茵河两岸的无障碍通道跑步。越野滑雪爱好者可在汝拉州绵延数公里的缓坡上滑行。驱车2小时不到,高山滑雪者和雪板滑雪者就可达到瑞士阿尔卑斯山的原始山坡上。
  • 在瑞士、德国和法国交界处,有各色吸引人的活动等着您:是参加阿尔萨斯的品酒会、巴登-符腾堡南部的美食盛宴,还是在汝拉州山峰上惬意地野餐?在巴塞尔地区,没有一小时车程里满足不了的需求。而且,总会有新发现!想在炎炎夏日跳进沁凉的河水中吗?这时,莱茵河岸线将成为名副其实的地中海里维埃拉——就在巴塞尔市中心。

唾手可及的各色活动、无与伦比的一流公共交通基础设施、安全和稳定的政治局势使得瑞士经常位居生活质量调查排行榜前列。这些都能在巴塞尔地区轻松获得,而艺术文化、生活方式和国际氛围更是锦上添花。因此不足以为奇的是,巴塞尔被瑞士年轻人视作瑞士最具嬉皮士精神和最时尚的地区之一。

我们的服务
Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

联系我们

投资巴塞尔地区

您的公司正在扩张吗?您正计划立足欧洲和瑞士,借以打入新市场吗?如是,那么巴塞尔地区正是您的理想之选。您将发现让您长久立于不败之地的要素近在咫尺。

众多跨国公司(主要是生命科学领域)确保了真正国际化的商业环境。巴塞尔地区拥有具有国际思维的人才库,整条价值链和各个职能环节都有高技能人才。巴塞尔地处欧洲中部,毗邻法国和德国,因此可以提供良好的商业环境,以及瑞士闻名于世的生活品质。

您想了解在此地区投资的好处吗?我们很乐意为您展示。我们的专家将在贵公司扩张项目的各个阶段为您提出全面而专业的建议。

  • 评估:税务?就业市场?竞争对手?政府许可?产业环境?我们将根据您独特的项目要求,收集巴塞尔地区及瑞士的所有相关信息和数据。
  • 选址:有任何待解决的问题?我们将寻找合适的专家为您答疑解惑。我们会将您介绍给政府机构、行业和法律专家,并在您置业的过程中提供专业支持。
  • 实地考察:您想亲自了解巴塞尔地区吗?我们将完全根据您的需求精心定制一份高效的实地考察计划和行程。
  • 商业开发:您想让公司业务增长提速吗?我们将帮助您建立与本地合作伙伴和机构之间的联系,加快您进驻巴塞尔地区高度多样化商业和创新生态系统的步伐。                                      

我们的服务将免费提供给那些正考虑择址巴塞尔的公司,这也有助于营造充满活力的商业环境。创新和接受新理念的开放心态是巴塞尔地区的悠久传统。我们期待听取您的商业理念,并协助您一开始就取得成功。

Gabriela Güntherodt

您的联系人

Gabriela Güntherodt

Member of the Management Board, Head of International Markets & Promotion

联系我们
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship


Tel. +41 61 295 50 15

sebastien.notexisting@nodomain.commeunier@baselarea.notexisting@nodomain.comswiss

为创新者牵线搭桥

“为创新者牵线搭桥”服务将创新构想、企业和企业家召集在一起。该服务有两种形式,一种是瑞士巴塞尔大区经济及创新促进局组织的非正式的专家活动,另一种是正式的针对性支持服务,为具体项目提供专家、合作伙伴和融资。我们的专家拥有8000多名创新者组成的强大网络作为后盾。

“为创新者牵线搭桥”服务主要面向以下五大核心主题领域:生命科学、医疗技术、信息与通信技术、生产技术和微技术、纳米技术和材料。每个技术领域都由一名专家专门负责。技术领域经理与行业展开密切合作,制定活动计划,担任项目的联系伙伴,与巴塞尔地区相关研究机构和其他机构培养伙伴关系。

因此,“为创新者牵线搭桥”服务为客户提供了立足于巴塞尔地区、从其多样化创新生态系统受益的理想入口。企业家、创新者和专家每年在逾50场活动上汇聚一堂,定期交流理念和知识,活动形式多种多样:

专题活动:专注于知识转移,为公司、特别是新创公司提供介绍公司和项目的机会,促进巴塞尔地区的创新者进行跨公司和跨学科的经验和知识交流。
研讨会:以拓展新技术应用范围以及发起具体项目和合作企业为目的,通过加强各个公司和学科的专家之间的对话,深度探讨某个主题。
技术与创新圈:运行多年的创新举措,目的是在各个公司和学科所组成的社区中进一步开发主题,以及探索新的市场潜力。

瑞士巴塞尔大区经济及创新促进局的支持创业服务为处于初创阶段的企业提供针对性的活动和服务。

Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship


Tel. +41 61 295 50 15

sebastien.notexisting@nodomain.commeunier@baselarea.notexisting@nodomain.comswiss
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship

联系我们

支持创业

您正计划创业?这太好了,因为巴塞尔地区以创业为生。瑞士巴塞尔大区经济及创新促进局作为巴塞尔地区创新和外来投资的推进机构,为技术和创新领域的企业家提供支持。

我们服务的核心内容是研讨会及工作坊项目:

  • 创始人课程:扶持性服务的核心内容是我们的研讨会及工作坊项目。“创始人课程”基本套餐的目标群体是计划创业的所有意向方。可在此浏览其他课程的概述:课程概述

    更多服务是专门针对在创新和科技领域有具体项目的初创公司和企业家:
     
  • 企业家研讨会及工作坊:在这些活动中,可以就各种商业问题,例如商业计划、融资、产品开发、定价和知识产权,以及营销与沟通进行深入探讨。这一系列活动专门针对有具体创新项目的初创公司和高科技中小型企业。

    除了培训课程和研讨会之外,瑞士巴塞尔大区经济及创新促进局还提供针对具体项目的单独咨询服务。该咨询服务专门针对创新和科技领域增长潜力巨大的公司和项目。
     
  • 联系与咨询:在初期咨询中,我们的专家将评估对支持的需求,并与专业人士、研究机构或潜在合作伙伴建立联系。
  • 新企业评估:在有专人指导下的流程和单独召开的专家会议中,初创公司和创新型中小企业可以请知名的行业专家、企业家和投资人对其商业项目进行评审。更多信息

    瑞士巴塞尔大区经济及创新促进局的服务涵盖创业的初期阶段。目标是在初期构想到实际创业,再到首个实施计划和融资的过程中,提供宝贵信息和切实的建议。这不仅给予企业家更多安全保障,而且可以显著加快他们实施项目的速度。
Sebastien Meunier

您的联系人

Sebastien Meunier

Member of the Management Board, Head of Innovation & Entrepreneurship

联系我们
Gabriel Schweizer

您的联系人

Gabriel Schweizer

Senior Project Manager Asia


Tel. +41 61 295 50 13

gabriel.notexisting@nodomain.comschweizer@baselarea.notexisting@nodomain.comswiss

进驻中国市场

过去几年中,中国作为商业市场的重要性不断提升。中国不仅是低成本消费品生产的海外目的地,也逐渐成为全球主要销售市场。将业务扩张到中国市场将给予公司巨大的发展潜力,尤其是对于中小型高科技公司而言。但想在中国这样复杂的市场占据一席之地,并非易事。

因此瑞士巴塞尔大区经济及创新促进局为巴塞尔地区(巴塞尔城市州、巴塞尔乡村州和汝拉州)的公司提供全面支持,从初期的市场评估、公司考察,直至寻找到商业合作伙伴。除了提供必要的专业知识外,我们的顾问还拥有良好的本地人脉,这些都是多年来与政商界往来所积累起来的。瑞士巴塞尔大区经济及创新促进局还构建有一个颇具规模的公司和专家网络,他们有与中国打交道的丰富经验,了解所有最新发展趋势。

具体而言,客户公司可以从下列服务中受益:

  • 联系与咨询:提供在中国设立经营业务的基础知识,以及由瑞士全球企业(Switzerland Global Enterprise)的专家提供的一对一的个案咨询。
  • 公司和代表团访问:除正式访问计划外,还可与潜在商业伙伴单独建立联系。
  • 活动:以开发新的共同商业潜力为目标,深化中国与巴塞尔地区的交流。

生命科学公司同样能从与上海张江高科技园区和新建的枫林生命科学园区的合作关系中受益,借此打入中国领先的生命科学枢纽。久经考验的中国本地合作伙伴可以提供支持,协助在上海开展业务(包括产品注册、融资、营销等)和与潜在商业合作伙伴及客户建立联系。

Gabriel Schweizer

您的联系人

Gabriel Schweizer

Senior Project Manager Asia


Tel. +41 61 295 50 13

gabriel.notexisting@nodomain.comschweizer@baselarea.notexisting@nodomain.comswiss

我们的渠道: 活动|博客

report BaseLaunch

“IP protection is crucial for business and research”

08.05.2018

The patent law and attorney-at-law firm Vossius & Partner has been an important partner for BaseLaunch since the inception of the healthcare accelerator in 2016. They advise startups and big corporations alike on IP strategy. Philipp Marchand, patent attorney in the Basel office, advocates to take IP protection seriously.

BaselArea.swiss: Vossius & Partner maintains offices in Munich, Düsseldorf, Berlin and Basel. How do you fit in the Swiss and Basel ecosystem?

Philipp Marchand: Our firm was founded in the 1960s, coming to Basel eleven years ago. We have developed extensive and profound in-house knowledge concerning all IP issues and currently represent clients of all sizes from startup companies to big pharma in Switzerland and all over the world. Basel, as one of the most exciting life science locations, is of particular interest to our firm, which has one of the largest life science groups in Europe.

That sounds a bit sophisticated for startups.

Not at all. Our expertise obtained from representing clients of all sizes is a huge advantage for the startup sector. Moreover, instead of considering IP issues in an isolated way, we endeavour to take all possible future developments of our cases into account. This includes considering aspects from other jurisdictions since, even as a startup, you have to be aware of potential worldwide implications right from the start. In addition, we work with our attorneys-at-law to not only protect an invention but also to provide advice on related aspects such as freedom-to-operate.

You are also involved in BaseLaunch. Why is that?

We entered into a partnership with BaseLaunch in order to be closer to the startup community in Basel and Switzerland. We meet with each of the selected companies and review their IP situation free of charge in order to identify potential ways to optimize protection. We are excited to be able to offer our expertise more frequently to startups because we believe that they genuinely benefit from our full service approach. If they wish, later they can also enter into a client relationship and benefit from our experience right from the start. Of course, we then have to charge for our services. However, we offer a very reasonably priced system for startup companies and universities.

Why is it worth it to spend that money?

IP protection is crucial in all technological fields and in more than one aspect: It is the only reliable means to ensure that you can make a profit in the long run in different markets worldwide. For a startup company working in life sciences, or any other technological field, the most important type of IP is without a doubt a patent right. Specifically, only a patent grants you the monopoly to keep third parties from using your invention. However, further IP topics are relevant at an early stage, too. For example, a trademark protecting the company’s name or its products that are put on the market can be invaluable. Without trademark protection a startup may be forced to change its name or the names of their products, which can incur considerable costs.

What if a researcher has no intention to commercialize his or her invention right-away?

You might think keeping your invention a secret is a good idea. But in the meantime another bright mind might have the same idea and file for patent protection. Today all jurisdictions, including the US, follow the “first to file” principle, which means that you may have missed your chance and you could even be sued for infringement by a third party for using what you thought was your own invention. We therefore strongly encourage inventors and their employers to file for IP protection as early as possible.

What do I need to protect an invention?

We like to discuss everything with our clients in person to fully understand the potential product as well as its market and its customers. Afterwards, we draft the patent claims, which means that we define the invention and the technical problem that it solves. We file the application text with a patent office, usually with the European Patent Office (EPO) as part of the European Patent Organization of which Switzerland is also a member. One year after the first filing, we can prepare a subsequent application, which covers more than 150 states worldwide. The whole process until an application is granted can take more than five years.

Is there a difference in the importance of IP protection in the life sciences sector compared to other fields?

The biggest difference is the longer product life cycle for pharmaceutical products and the stricter regulations compared to, say, short-lived computer hardware. Also, due to the long product life cycles and general development costs in this sector, patent protection is the only way to ensure that the owner of the patent right benefits first from the invention. With a particular focus on the pharma sector, one should also mention the need to build-up an IP portfolio which not only protects, for example, a drug but also the process of making that drug, different formulations, dosage and treatment regimens and so on. At the same time, you should consider using additional IP rights such as trademarks. Take Bayer who invented Aspirin. The patent for the active ingredient acetylsalicylic acid has long expired, which means it may be widely produced and sold. However, the trademark still ensures that people specifically ask for Aspirin.

Are there any reasons to advise against filing for patent?

Yes, of course. There are situations where it may make sense to wait with filing a patent application until sufficient data and support has been collected. For example, it may not always be advisable to file a patent for a research platform to protect a screening method for active compounds. This is because patent applications are published 18 months after filing, meaning that everyone has access to the method. In this scenario, it may make sense to wait for the first molecule that emerges from your platform and file for product protection. However, such strategic aspects should always be discussed on a case-by-case basis.

Which misconceptions concerning IP do you sometimes encounter?

Most researchers are aware of IP protection but the execution could be better. One misconception includes the so-called grace period. There is no grace period in European patent law or in most other jurisdictions with the exception of the US, Japan and Canada. After you publicly disclose your own invention by writing or talking about it, you may not be able to obtain patent rights for your invention.

What may researchers reveal to their peer collaborators?

An invention is new if it does not form part of the state of the art, meaning it is not publicly known. Hence every discussion with a colleague or presentation of a poster at a conference prior to filing a patent application can potentially destroy the novelty. You may think that no one will find out. However, when it comes to money, third parties will leave no stone unturned. Of course, we are aware of the conflict between patent applications and the need to publish academic papers or give presentations. If you are unsure what to do: It is always better to come talk to us before a publication, a poster presentation or any other public disclosure, even on short notice.

 

About
Philipp Marchand heads the Basel office of Vossius & Partner. After graduating in biochemistry at the University in Frankfurt am Main and his PhD studies at a CNRS institute in Paris, he started his career as a patent attorney trainee with Vossius & Partner in Munich. After the bar examination, he transferred to Basel at the beginning of 2017. Recently, he started to pursue a doctorate in law at the University of Basel. Vossius & Partner is a leading patent law firm offering a full-service concept with legal competence from patent attorneys in every technological sector and attorneys-at-law qualified to practice not only in Europe and Switzerland, but also in the United States, Japan, Taiwan and Korea. The firm employs 55 patent attorneys and 20 attorneys–at-law in their offices in Munich, Düsseldorf, Berlin and Basel.

report Innovation

Panalpina joins blockchain alliance

24.05.2018

event Production Technologies

Production Technology Circle Industrie 4.0 «Produktivität in der Industrie 4.0»

Date: 28.05.2018

Place: Business Park Laufental & Thierstein, Riedstrasse 8, 4222 Zwingen

report BaselArea.swiss

Connecting Innovators App Launch

11.04.2018

How the BaselArea.swiss-App connects innovators and supports an innovative idea.

One of the major assets of BaselArea.swiss is its broad network, which has been confirmed time and again by the participants of our seminars, workshops and conferences. To simplify the networking during and after the events, BaselArea.swiss launches the App “Connecting Innovators” together with SAS Papott.

The use is simple: After downloading the app from Google Play or from the App Store, connect with your LinkedIn account and complete your profile. You will see the other event attendees in a list with their name and picture, filtered according to proximity to your location, thus facilitating connect with other participants. Not only will you see which users attend the same events but it is also easier for specialists to connect to people with similar interests or for entrepreneurs to approach potential investors.

Networking made simple

Originally, the developer and founder of SAS Papott, Maxime Vitrey, had the vision of improving our ability to connect with our fellow human beings on a more general level. He designed an open app and everybody who created a profile could see who is close by. “I wanted to make it easy for everybody to get in touch with each other.” He also realized the potential the technology holds for networking at conferences. “I know from personal experience how hard it is to get in touch with other participants I do not know yet”, Maxime says. The challenges are manifold: Groups of people who stay together because they know each other already; name tags that are hard to read; the slightly impolite act of interrupting people who are engaged in conversation. And last but not least: finding the people you should talk to because you share the same area of interest.

The World of entrepreneurship

After attending a startup seminar organized by BaselArea.swiss, Maxime approached Sébastien Meunier, Head of Innovation & Entrepreneurship, to suggest creating an application according to the needs of the organization. “We quickly decided to give it a shot”, says Maxime. Being a seasoned project manager, he developed new techniques and gained experience during the implementation of the project since the whole value chain was in his hands. Currently, he approaches new customers to build clones of the app. He sees potential to ease interaction in large companies during meetings or amongst their employees. Further, the technology could be used in hospitals to allow patients to socialize with other patients. While Maxime still works for his long-term employer, Jet Aviation, he is also pleased that his entry into the world of entrepreneurship is successful. “It is extremely exciting to finally be the entrepreneur I always wanted to be.”

For BaselArea.swiss, the app allows the participants of the more than 70 events per year to be served even better: “The app helps to strengthen one of our core disciplines in creating an open and supportive business culture - a solid network with approachable members,” says Sébastien Meunier. “We are looking forward to seeing a lot of our participants using it.”

Join us to keep networking simple, efficient and useful. Download the app “Connecting Innovators” from Google Play or from the App Store and let us know what you think.

report Life Sciences

Novartis receives U.S. approval for migraine medication

22.05.2018

event Supporting Entrepreneurs

Boost your profits and value with Innovation Excellence in pharma

Date: 29.05.2018

Place: Business Parc Reinach, Christoph Merian-Ring 11, 4153 Reinach

report ICT

“A good network is power”

03.04.2018

Melanie Kovacs was frustrated by the IT teaching she got, and developed her own product – Master21. She attributes her success with this not least to her carefully maintained network, which has continued to grow in Basel. Melanie Kovacs and her fellow campaigners use the technology and innovation network “We Shape Tech” to promote diversity by making women working in the technology and innovation field more visible.

Ms Kovacs, you founded Master21 when you were 28. How did that come about?

As a co-initiator of the Aspire network for women startup owners, I’d met a lot of very interesting women. One of them was Valérie Vuillerat, the managing director of Ginetta. She offered me a job, and I took it. At the agency I was the link between clients and developers. I worked closely with the people from the technical area, but I didn’t speak their language. Then I went back to taking courses at the university. But this was dreadfully theoretical, boring front of class teaching, and I didn’t enjoy it at all. I was sure that anybody can learn programming, but I felt it had to be done differently.

So what is your company doing better?

We do exactly what I was missing at the time. We put people without a technical background in a pleasant atmosphere and use lots of practical exercises to give them sufficient competences and self-confidence in programming. Most of them are like me – they don’t necessarily want to embark on a new career, they want to work with developers on a solid basis. That’s why at Master21 you learn the fundamental terms and concepts and understand how design, front end, back end and databases fit together. Participants learn HTML, CSS, Javascript and Ruby and try out for themselves how object-oriented programming works.

How did the start-up process work out?

I started a pilot project for Master21 while I was still working at Ginetta. The fluid transition was ideal for me. My co-founder is responsible for the technical side and content, I’m responsible the business aspect. I’m very happy that he gave me the push I needed to start. I’m not sure I would have dared to found a company on my own. A few months ago, we hired a new employee. I find it very motivating if every initiative doesn’t depend on me and I can work with a team.

What do you most appreciate about being an entrepreneur?

I can set my own schedule for the day, I’m learning a lot and I work every day with bright, exciting people. I’m also seeing that my services are directly influencing the students. There have already been two cases where people met on the course and subsequently started a project together. It’s more difficult to find developers who like teaching and are good at it.

What happens next with Master21?

I’m currently participating in the Entrepreneurs’ Organisation’s Accelerator Programme, and I’m also working with a coach. Currently I’m not at all interested in a financing round, because I’d like to continue to grow independently of investors. I want the firm to develop, but at my own pace and with long-term prospects.

The company’s headquarters are in Zurich, you live in Basel. What happens where?

I’m in Zurich when I’m working at the Impact Hub and want to meet people. The courses have also been held there so far. In Basel I work on corporate strategy in my home office and write texts. If things get too quiet for me, I go to the “Unternehmen Mitte” establishment and work there, or I meet someone for lunch at the Markthalle. I think it's because there are so many expats in Basel that there’s a great sense of openness there.

How important is your personal network for the success of Master21?

My network is absolutely central. At the start, I emailed every single one of my contacts, told them about my new project and asked for feedback. I maintain my network by LinkedIn and email, and I go and have coffee with people regularly. I also go to events like TEDxZurich, and I’m active in We Shape Tech.

You’re an enthusiastic networker.

Yes, it’s easy for me. For many people networking has such a negative image. I’m not interested in collecting business cards; I want to get to know people. And I’d much rather talk to one person than quickly give my card to a whole lot of people. I really enjoy networking, because I can learn something from everybody. A couple of years ago I was just everywhere, including to promote my business. Now I find it boring if someone’s just presenting their pitch, and I’m better at choosing where I participate. I find networking particularly valuable if you can share your ideas on a joint topic with others in small groups.

You brought the initiative for diversity, the We Shape Tech network, which was previously already active in Zurich and Bern, to Basel. Why does Basel need this network?

Basel still has a lot of potential in the technology and innovation area. One indication of that for us was the way that we were welcomed with open arms. Our board member Elaine Skapetis is a developer at Adobe. The company supported us generously without hesitation with our first two Basel events. The hall at the launch event was filled to bursting, the response was just unbelievable. We offer people working or interested in the technology and innovation field the opportunity to share ideas and views and learn from each other. We follow a specific format here, where one person tells their story, a discussion is initiated, and there’s time for networking. Our goal is to connect people, communicate knowledge and ensure access to other organisations and partners. Knowledge and a good network are power.

What are the advantages of networks primarily aimed at women?

In Basel men are welcome at We Shape Tech as well. To promote diversity, you need both men and women. However, sadly, only a few men have taken advantage of the opportunity to date. The few men at the meeting have an experience which women often have, namely being part of a minority. If you have a group of just women, the atmosphere is more relaxed. I also see this in courses specifically for women at Master21. If women are just with other women, they trust themselves to do more. They ask questions which they wouldn’t if men were present, say more and are more confident than if there were men there.

About Melanie Kovacs
Melanie Kovacs founded Master21, where people interested in courses with practical relevance are introduced to the fundamentals of programming. Previously, she has founded the women’s network Aspire, and organised start-up weekends. She studied business administration at the Zurich University of Applied Sciences in Business Administration and the University of Madrid and completed a CAS in requirements engineering at the University of Applied Sciences, Rappers. Together with Aileen Zumstein and Elaine Skapetis, Melanie Kovacs brought the network We Shape Tech to Basel. The Movement in Diversity initiative offers a platform and community for people who want to make a difference in the hi-tech and innovation area. The organisation focuses simultaneously on communicating knowledge and promoting the exchange of ideas.

report Invest in Basel region

First of its kind in Switzerland: The Center for Innovative Finance

22.05.2018

event BaselArea.swiss

Workshop Kommunikation & PR für Technologieunternehmen

Date: 30.05.2018

Place: BaselArea.swiss, Dufourstrasse 11, 4010 Basel

report BaselArea.swiss

Die Wirtschaftsregion Basel-Jura entwickelt sich stabil

28.03.2018

Die Wirtschaftsregion Basel-Jura bietet Unternehmen ein erstklassiges Umfeld. Dies das Fazit des aktuellen Jahresberichts 2017 von BaselArea.swiss.

In ihrem Jahresbericht 2017 zeigt sich BaselArea.swiss zufrieden mit der Entwicklung der Region Basel-Jura. Zwar pendelte sich die Zahl der von der Innovationsförderung und Standortpromotion der Kantone Basel-Landschaft, Basel-Stadt und Jura betreuten Ansiedlungen nach dem Rekordjahr 2016 wieder auf Vorjahresniveau ein. Gemessen an der Anzahl der geplanten Arbeitsplätze in den kommenden drei bis fünf Jahren knüpft das Ergebnis jedoch ans 2016 an. «Dies ist angesichts der erschwerten Rahmenbedingungen ein gutes Resultat», freut sich CEO Christof Klöpper. Insbesondere habe die Ablehnung der Unternehmenssteuerreform III zu Verunsicherungen auf Kundenseite geführt.

Bezüglich geografischer Herkunft und Tätigkeitsfeld der angesiedelten Unternehmen dominierten einerseits die USA sowie die Life Sciences (inklusive Chemie). Zu den grösseren Ansiedlungen zählten: Bio-Rad (USA), die in Basel den Europäischen Hauptsitz eröffneten, Idemitsu (Japan), die in Basel ein Forschungszentrum für organische Leuchtdioden einrichteten, sowie SpiroChem, die ihren Hauptsitz von Zürich nach Basel verlegten. Zudem gelang es, die Pipeline mit neuen Ansiedlungsprojekten zu füllen: So besuchten im vergangenen Jahr 90 Firmen im Rahmen einer Standortevaluation die Region.

Mehr Unternehmertum

Positiv entwickelten sich die Unternehmensgründungen in der Region Basel-Jura. So verzeichnete BaselArea.swiss eine erhöhte Nachfrage nach Dienstleistungen im Bereich Supporting Entrepreneurs und konnte mehr als 60 Neugründungen und Start-ups unterstützen. Die von BaselArea.swiss organisierten Veranstaltungen, Seminare und Workshops brachten über 5500 Teilnehmende zu Innovationsthemen zusammen, was ebenfalls ein deutliches Plus gegenüber dem Vorjahr darstellt.

BaselArea.swiss gelang es im Jahr 2017 eine Reihe von Aktivitäten in neuen, für die Region wichtigen Innovationsthemen anzustossen. So wurden die Aktivitäten im Bereich Industrie 4.0 ausgebaut. Diese sollen im 2018 mit Partnern aus dem benachbarten Ausland innerhalb eines Interreg-Projekts weiterentwickelt werden.

Ein weiterer thematischer Schwerpunkt fokussiert auf Innovationen in der chemischen Industrie. Unter dem Namen DayOne wurde 2017 eine vielbeachtete Initiative zum Thema Precision Medicine und Digital Health lanciert.

Überaus erfolgreich erwies sich der im 2017 lancierte Healthcare Accelerator BaseLaunch. Nicht nur gelang es mit Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer und Roche sowie Roivant Sciences die Unterstützung von fünf Industrieschwergewichten für den Accelerator zu gewinnen. Auch am Markt wurde BaseLaunch gut aufgenommen: Über 100 Bewerbungen von Start-up-Projekten aus mehr als 30 Ländern gingen bei BaselArea.swiss ein. Sechs Start-up-Firmen werden nun in der Region Basel-Jura gegründet und während eines Jahres beim Firmenaufbau mit bis zu 250'000 Franken sowie Infrastrukturleistungen im Switzerland Innovation Park Basel Area unterstützt.

report Life Sciences

Most exciting biotechs are based in Basel

17.05.2018

event Production Technologies

Pharma Digitalization: Now & Future Trends

Date: 01.06.2018

Place: Auditorium on Ground Floor of Building 683 of F. Hoffmann-La Roche AG, Viaduktstrasse 33, Basel

report Life Sciences

“I enjoy thinking about seemingly unsolvable problems”

13.03.2018

Andreas Plückthun continues his research where others stop: 40 employees work in his laboratory on protein engineering. Their results form the basis for three biotech companies: Morphosys in Munich, as well as Molecular Partners and G7 Therapeutics (today Heptares Zurich) in Schlieren. At the Antibody Congress 2017 in Basel, Andreas Plückthun told us why he remains true to his research.

Mr. Plückthun, you co-founded three biotech companies in three decades. How did this come about?

There was always this curiosity in the beginning to discover something – but never the wish to found a company. After we produced artificial antibodies and learned how to mimic the immune system, we established the company Morphosys. Then the next question arose: can we do this with other protein molecules and solve new problems? Out of this emerged Designed Ankyrin Repeated Proteins (DARPins) and a second company, Molecular Partners in Schlieren. The next challenge was then to stabilize receptors by means of protein engineering in order to develop better drugs for these points of attack. Based on this research, we founded the third company, G7 Therapeutics.

Who pushed ahead with the spin-offs each time?

For the first company, it was my research colleagues. I was the more sceptical of us three at the time. The other two companies were traditional spin-offs of my doctoral and postdoctoral students.

How are the companies doing today?

Morphosys now has 430 employees and recently celebrated its 25th anniversary. We also received the first FDA approval for an antibody that is now available on the market. This is one of the few companies that is still doing exactly what we once wrote in the business plan, and successfully too. Molecular Partners has 130 employees, several Phase 2 and 3 studies, and, like Morphosys, is listed on the stock exchange. G7 Therapeutics was sold to the British company Heptares, which in turn belongs to the Japanese company Sosei. In short: all companies are doing well. I don’t consider founding a company to be a particular achievement. The achievement is more that the companies are flourishing and bringing drugs to the market.

What changes have you noticed over the decades when it comes to founding a company?

The climate has changed completely. It was totally against the grain in Europe 25 years ago to found a biotech company. That’s why people went to California. At a symposium in America, I was once introduced as a researcher and a founder with the words; “He’s like us.” It was very common there for a long time to be both a researcher and an entrepreneur. That scepticism has since disappeared here, and founding a company is now judged positively. A venture capital scene has also developed since then. To be fair, I have to say that it helps investors if you’ve already successfully founded a company. The first deal is always the hardest.

You seem to be quite successful when it comes to founding companies. Did it ever tempt you to move to one of your companies?

It was never a question for me to leave the university. It’s an incredible privilege to be paid by the state to do crazy things. I always wanted to think about the next challenge at the university. Not having to account for quarterly profits is the only way forward in this context. In a company that conducts research with money from investors, you simply cannot undertake the type of risky and long-term projects that interest me. But I can say that thanks to the companies that are based on my research, I have repaid my dividends and created many jobs.

So you’ll continue to devote yourself to basic research. Can this be steered towards commercialization at all?

We’ve always wanted to solve a problem that seemed important enough to us. At some point in the research the question arises of how to use the results, what you can make of them. If we hadn’t commercialized the results, the problems would have simply stopped at an interesting point. We would have stopped halfway along. This is comparable to a coming up with blueprint for a computer and then not building it. By founding the companies, we could ensure that the projects would continue.

Is there any collaboration with industry within the scope of your research?

Direct collaboration between the pharmaceutical industry and our laboratory has never worked properly. Expectations and time horizons are very different. We develop new ideas and concepts that are often not exactly in keeping with large-scale pharmaceutical research. I don’t think anyone will feel offended when I say that the pharmaceutical industry is very conservative. We do have many contacts but hardly any collaboration. That being said, our spin-offs work very well with the pharmaceutical industry.

Which topics would you like to focus on next?

We are researching artificial viruses that cannot reproduce. The viruses should produce proteins directly in the body that are needed as therapeutic agents. This is so far away from practical implementation that such a project is only possible at a university. But I am absolutely convinced that it would have enormous significance if it worked. I couldn’t sit still if we didn’t at least try. We are once again trying to solve a problem in my laboratory that most people in the field would consider impossible to solve. That’s what makes me get up in the morning. I want to show how it works.

Learn more about Andreas Plückthun between basic research and biotech entrepreneurship at our event on 24 April 2018.

About
Andreas Plückthun (*1956) is a scientist whose research is focused on the field of protein engineering. He is the director of the department of biochemistry at the University of Zurich. Andreas Plückthun was appointed to the faculty of the University of Zurich as a Full Professor of biochemistry in 1993. Plückthun was group leader at the Max Planck Institute of Biochemistry , Germany (1985-1993). He was elected to the European Molecular Biology Organization (EMBO) in 1992, and named a member of the German National Academy of Science (Leopoldina) in 2003. He is cofounder of the biotechnology companies Morphosys (Martinsried, Germany), Molecular Partners AG (Zürich-Schlieren, Switzerland) and G7 Therapeutics (Zürich-Schlieren, Switzerland).

Interview: Annett Altvater and Stephan Emmerth, BaselArea.swiss

report Precision Medicine

BC Platforms partners with Google Cloud

15.05.2018

event Innovation

Wie Technologie 4.0 uns weiterbringt

Date: 05.06.2018

Place: LOKAMI Restaurant, Bar & Lounge, Elsässerrheinweg 101, 4056 Basel Switzerland

report BaseLaunch

Meet the BaseLaunch Startups

11.03.2018

Six of the BaseLaunch startups recently started Phase II. They received either grants up to 250,000 Swiss francs or gained free of charge access to BaseLaunch laboratory and office space at the Switzerland Innovation Park Basel Area. Hear what the startups, the BaseLaunch team and selection committee members experienced in the first year. Find out more about what makes BaseLaunch unique.

The BaseLaunch accelerator is now open for applications for the second cycle. Entrepreneurs with a healthcare based project or a game-changing innovation in diagnostics, medtech or related field at the pre-seed or seed funding stage are invited to submit their applications to the program.

Following the application deadline on 14 May, promising projects will be admitted to the accelerator program for a period of 15 months. In phase I, the startups will benefit from the support of industry experts, office- and laboratory space free of charge and access to healthcare partners. After three months, they will be invited to present their idea to the selection committee. They will determine which promising startups will proceed to Phase II that runs for one year.

BaseLaunch is backed by five industry leaders — Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and Roivant Sciences. Other public and private partners such as KPMG and Vossius & Partner also support the initiative.

report Invest in Basel region

Abberior Instruments GmbH opens subsidiary in Basel

14.05.2018

event Supporting Entrepreneurs

Bring your market and competitor analysis to the next level

Date: 05.06.2018

Place: BaselArea.swiss, Dufourstrasse 11, 4010 Basel